Key points from article :
Synchron has been cleared by the FDA to begin a clinical trial with human participants.
The COMMAND trial will take place later this year in New York and will include six patients with severe paralysis.
Device is implanted into the motor cortex of the brain through the jugular vein.
A minimally invasive procedure that takes about two hours.
Translates brain activity to allow users complete tasks on external devices (texting, emailing, online shopping and accessing telemedicine).
Synchron has begun studying the effects among paralysis patients in Australia.
Showed that the participants could type on their devices with only their thoughts.
Data from the first two patients in the study were published in the Journal of NeuroInterventional Surgery.
Scored $40 million in Series B funding for its implantable brain-computer interface tech.
“Synchron’s north star is to achieve whole-brain data transfer,” - Thomas Oxley, CEO of Synchron.